Abstract Details

Title Sustained Benefit with Repeated Treatments of OnabotulinumtoxinA in Post-Stroke Lower Limb Spasticity: 1-Year Open-Label Final Results from a Double-Blind, Placebo-Controlled, Phase 3 Trial

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) (-)

Poster/Presentation
Number 002

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Theodore Wein, MD (Montreal General Hospital) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Lynn M. James (Allergan Plc)	Ms. James has received personal compensation for serving as an employee of AbbVie. Ms. James has stock in AbbVie.
	No disclosure on file
	No disclosure on file
Rozalina Dimitrova, MD, MPH (Allergan, Inc)	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��